Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Average Rating of “Moderate Buy” by Analysts

Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) have been given an average recommendation of “Moderate Buy” by the fourteen research firms that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and twelve have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued a report on the stock in the last year is $36.1429.

A number of equities analysts have weighed in on VRDN shares. The Goldman Sachs Group decreased their price target on Viridian Therapeutics from $36.00 to $31.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Monday, April 20th. Royal Bank Of Canada upped their target price on Viridian Therapeutics from $30.00 to $34.00 and gave the company an “outperform” rating in a research report on Wednesday, May 6th. Needham & Company LLC reissued a “buy” rating and set a $32.00 price target on shares of Viridian Therapeutics in a research report on Tuesday, May 5th. Finally, Stifel Nicolaus set a $39.00 price target on shares of Viridian Therapeutics in a research report on Wednesday, May 13th.

Insider Buying and Selling at Viridian Therapeutics

In related news, Director Fairmount Funds Management Llc purchased 1,176,470 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average price of $17.00 per share, with a total value of $19,999,990.00. Following the completion of the transaction, the director owned 5,090,928 shares of the company’s stock, valued at $86,545,776. This represents a 30.05% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 2.40% of the company’s stock.

Institutional Investors Weigh In On Viridian Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in VRDN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Viridian Therapeutics by 1.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after acquiring an additional 876 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Viridian Therapeutics by 33.8% in the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock worth $16,595,000 after buying an additional 310,998 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Viridian Therapeutics by 12.8% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company’s stock worth $1,760,000 after buying an additional 14,788 shares during the period. Envestnet Asset Management Inc. bought a new position in shares of Viridian Therapeutics in the second quarter worth $187,000. Finally, Creative Planning bought a new position in shares of Viridian Therapeutics in the second quarter worth $179,000.

Viridian Therapeutics Price Performance

Shares of NASDAQ:VRDN opened at $16.63 on Monday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.15 and a current ratio of 15.15. Viridian Therapeutics has a 1 year low of $13.18 and a 1 year high of $34.29. The stock has a market capitalization of $1.71 billion, a P/E ratio of -5.01 and a beta of 0.90. The stock has a 50-day simple moving average of $16.01 and a 200-day simple moving average of $24.71.

Viridian Therapeutics (NASDAQ:VRDN) last released its quarterly earnings results on Tuesday, May 5th. The company reported ($0.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.16. The firm had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.04 million. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.Viridian Therapeutics’s quarterly revenue was up 95.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.87) EPS. Equities analysts forecast that Viridian Therapeutics will post -3.87 earnings per share for the current year.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.